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 CURRENTOPINION Transfusion strategy in multiple trauma patients
Oliver M. Theusinger, Philipp Stein, and Donat R. Spahn
Purpose of review
To point out the tolerance of anemia, the possible use of alternatives to allogeneic blood products as well
as the pathophysiological effects of transfusions in the context of multiple trauma patients.
Recent findings
Restrictive transfusion triggers are beneficial for patient outcome in trauma.
The actual European Trauma Treatment Guidelines suggest the use of point-of-care devices, the use of
transfusion algorithms and factor concentrates to control coagulopathy. The use of high ratios of plasma to
red blood cells to improve survival has been shown to suffer from a time-dependent survival bias. In
massive bleeding, factor-based treatment of coagulopathy is feasible and preferable to plasma transfusion,
if available. In nonmassive bleeding, allogeneic transfusion of blood products increases the appearance of
serious adverse events and mortality and should be avoided unless clearly indicated.
Summary
Transfusion in trauma has to be an individual decision for a specific patient, not for a specific laboratory
value. Transfusion management must aim at reducing or even avoiding the use of allogeneic blood
products. This may lead to a new gold standard with cost reduction and amelioration of outcome of major
trauma patients.
Keywords
allogeneic blood products, assessment of anemia, pathophysiology of transfusions, transfusion triggers,
trauma
INTRODUCTION
Mortality related to traumamay be up to 40% in the
civilian sector [1
&&
,2,3]. Of those 40%, one quarter of
the deaths are related to coagulopathy and uncon-
trolled blood loss that may be preventable [4
&&
,5].
For this reason, treatment of coagulopathy and
hemostatic control are key to reduce mortality
due to exsanguination, to save blood products
and to improve outcome [1
&&
,6–11].
Using restrictive transfusion triggers and patient-
specific physiological reserve of anemia are the two
aspects that can also be applied in multiple trauma
patients to reduce the use of blood products
[12
&
,13
&
,14
&&
,15,16
&&
].
Point-of-care (POC) devices, such as rotational
thromboelastometry (ROTEM, TEM Innovations
GmbH, Munich, Germany) or thromboelastography
(TEG, Haemoscope Corporation, Niles, Illinois, USA)
are becoming more popular to treat bleeding in
trauma and are highly recommended to guide hemo-
static therapy during coagulopathy [1
&&
,17,18].
The purpose of this review is to enlighten
patient tolerance to anemia, the use of transfusion
algorithms and alternatives to allogeneic blood
products, the outcome of transfused patients,
complications and pathophysiological effects of
blood products as well as transfusion triggers and
thresholds to use blood products in a restrictive
manner.
PATHOPHYSIOLOGICAL EFFECTS OF
TRANSFUSION
Although blood transfusions are considered to be
well tolerated in first world countries with regard to
the direct transmission of infectious agents, there
are still some serious adverse events that need to be
mentioned. Although their frequency is low, hemo-
lytic and delayed hemolytic reactions are severe
adverse events [19]. They may be due to the trans-
fusion of AB0 incompatible blood product. Delayed
Institute of Anesthesiology, University Hospital of Zurich, University of
Zurich, Zurich, Switzerland
Correspondence to Oliver M. Theusinger, MD, PrivatDozent, Institute of
Anesthesiology, University Hospital of Zurich and University of Zurich,
Ra¨mistrasse 100, CH-8091 Zurich, Switzerland. Tel: +41 44 255 27 10;
fax: +41 44 255 44 09; e-mail: oliver.theusinger@usz.ch
Curr Opin Crit Care 2014, 20:646–655
DOI:10.1097/MCC.0000000000000152
www.co-criticalcare.com Volume 20  Number 6  December 2014
REVIEW
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
hemolytic reactions occur in patients who have
developed antibodies from previous (AB0 compat-
ible) transfusions or pregnancy. These antibodies in
question sometimes present in low concentrations
and are too weak to be detected by standard pro-
cedures at the time of antibody screening before the
intended transfusion. Subsequent transfusion with
red blood cells (RBCs) having the corresponding
antigen results in an anamnestic antibody response
and consecutive hemolysis of transfused RBCs.
Febrile reactions (a rise of 1.0 8C from baseline)
due to cytokines and antibodies to leukocyte anti-
gens reacting with leukocytes or leukocyte frag-
ments are common with a frequency of about
10% [19]. Foreign plasma proteins are able to cause
allergic reactions causing urticaria and may be
associated with laryngeal edema and broncho-
spasm; their frequency is about 1%. Anaphylactic
reactions are rare and may be due to an anti-immu-
noglobulin A reaction, leading to cardiovascular
instability, dyspnea, stridor, shock and possible
cardiac arrest. Transfusion-related acute lung injury
(TRALI) is underrecognized, and thus its frequency
is rare [20
&
]. The pathomechanism is supposed to be
linked to the presence of antibodies in the donor
plasma, which react with the recipient’s leukocyte
antigens or induce the production of inflammatory
mediators resulting in a noncardiogenic pulmonary
edema with a 10% fatality [21,22
&
]. Bacterial con-
tamination occurs when a small number of bacteria
enter a blood component during collection or proc-
essing. During storage, bacteria may proliferate,
resulting in a large number of organisms and endo-
toxins being given with the transfusion. This com-
plication is rare in first world countries but leads to
major complications including fatalities [23
&
].
In addition to the above-mentioned distinctive
side-effects, RBC transfusions in trauma patients
increase the risk of multiorgan failure, infections,
renal dysfunction, length of stay (LOS) and
mortality [24,25] .
Trauma patients are at greater risk for massive
transfusion. In addition, longer storage time of RBCs
[26–28] leads to even longer LOS [29,30], additional
occurrence of deep vein thrombosis [31] and even
higher mortality [26,30–33] with a possible dose
effect regarding older blood products [27,31,33].
ASSESSMENT OF ANEMIA IN TRAUMA
The initial hemoglobin or hematocrit measurement
is not a precise measure of the actual blood loss of a
trauma victim, particularly after a limited initial
fluid therapy. Therefore, a near normal hematocrit
value in the emergency department does not rule
out significant blood loss (low sensitivity) [34]. But,
a primarily low hematocrit has a high specificity in
identifying major injury and blood loss requiring
operative intervention [34,35]. Moreover, a low
hematocrit is associated with higher injury severity
scores, hypotension and acidosis [36]. Preexisting
anemia or severe hemodilution cannot be ruled out
as other reasons for a low hematocrit, but a drop in
the hematocrit value over time (serialmeasurement)
is sensitive and specific for bleeding, even in the
context of fluid resuscitation [37].
In 2002, Kinoshita et al. [38] were the first to
describe an apparatus to measure hemoglobin con-
centrations noninvasively using three different
wavelengths. The development of multiwavelength
pulse oximeters showed promising results and a
relatively acceptable accuracy in perioperative
patients when peripheral perfusion, indexed as
signal quality by the machine, was good (in 70%
of cases) [39]. However, for trauma patients, this
method is inadequate as shock, hypothermia and
vasoconstriction influence the results [40,41
&
]. In a
study comprising 525 trauma patients, detection
of a hemoglobin value was impossible only in
34% of the readouts [42].
Although noninvasive hemoglobin measure-
ment shows promising results in patients with an
adequate peripheral perfusion, it is not yet useful in
the setting of trauma and hemorrhagic shock to
guide transfusion decision making.
TRANSFUSION TRIGGERS AND
THRESHOLDS (THE EMPIRICAL
APPROACH)
Blood transfusion historically is thought to save
the life of bleeding patients, but no high evidence
data are available to date to support this axiom
[43].
In the perioperative setting, not referring
specifically to trauma victims, anemic patients have
a significantly higher perioperative 30-daymortality
after major noncardiac surgery, compared to con-
trols with normal hemoglobin levels [44,45].
KEY POINTS
 Also, in trauma, restrictive transfusion triggers are
beneficial for patient outcome.
 Goal-directed transfusion algorithms and the use of
POC devices in trauma reduce the need of allogeneic
blood products.
 There is no clear evidence for high FFP : RBC ratios as
this concept suffers from a time-dependent survival bias
in patients receiving high FFP : RBC ratios.
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However, allogeneic blood transfusion is not
the ‘cure’ for the anemic patient. Specific risks, such
as (viral) infection, TRALI, transfusion-related circu-
latory overload and immunomodulation, account
for the transfusion-associated worsened outcome
[46,47].
Formerly accepted hemoglobin transfusion trig-
gers of about 100 g/l were abandoned [48].
A Cochrane review concerning transfusion
triggers states that blood transfusion probably can
be withheld to hemoglobin levels of as low as 70 g/l.
The threshold for patients with coronary artery
disease remains to be exactly determined but is
likely at or below 80g/l. Further research is needed
to evaluate the role of even lower hemoglobin levels
[9]. A randomized controlled multicenter study
showed a lower mortality, fewer complications
and a shorter length of hospital stay in patients
with acute upper gastrointestinal bleeding when
transfused restrictively (Hb <70 g/l) as compared
with a more liberal transfusion regimen (Hb
<90 g/l) [49
&&
]. In hip fracture surgery patients with
a history of, or risk factors for, cardiovascular dis-
ease, liberal transfusion strategy (threshold 100 g/l)
did not reduce rates of death on 60-day follow-up or
reduce in-hospital morbidity in elderly patients
[50].
In 203 trauma patients, analyzed as a subgroup
of the prospective randomized controlled ‘trans-
fusion requirements in critical care’ trial [51], a
restrictive transfusion trigger (<70g/l) to maintain
hemoglobin between 70 and 90g/l was not inferior
to a liberal (>100 g/l) regimen with hemoglobin
concentrations between 100 and 120g/l. Patients
in the restrictive group received significantly fewer
allogeneic RBC transfusions. Reported 30-day all-
cause mortality, rate of multiorgan dysfunction,
LOS in the hospital and in the ICU were comparable
and not significantly different between the two
groups [51].
In patients with traumatic brain injury (TBI),
RBC transfusion increased local brain tissue oxygen
partial pressure in 74% of the patients [52]. How-
ever, this effect was not seen with ‘old’ blood stored
more than 19 days [53]. Despite increased oxygen
partial pressure, no positive effect on cerebral
metabolism was seen [54]. More days with a hem-
atocrit below 30% were associated with improved
neurologic outcomes in a retrospective analysis of
169 patients [55]. Transfusion, but not anemia,
significantly led to higher mortality and more com-
plications among 1150 TBI patients [56]. Increasing
the hematocrit above 28% in the initial operation
phase following severe TBI was not associated with
an increased or decreased morbidity or mortality
[57]. Initial anemia (Hb <100 g/l) in the emergency
department following TBI was not a mortality risk
factor [58].
The current knowledge gives no compelling
evidence to treat patients with severe TBI differently
in contrast to other critically ill patients concerning
RBC transfusion [1
&&
].
Clinical indicators such as injury severity score
above 25, the need for procedural bleeding control
[59
&
] and multiple scoring systems consisting of
international normalized ratio (INR), mechanism
of injury, positive results for focused assessment
with sonography for trauma, blood pressure, initial
hemoglobin and heart rate can help identify trauma
patients at risk for massive transfusion, but also
patients highly unlikely to need a massive trans-
fusion [60
&
,61]. These variables and scores may be
used as an adjunct to guide resuscitation, but they
do not reflect the specific needs of an individual
trauma victim.
Emphasis must be put on the fact that trans-
fusion has to be an individual decision for a specific
patient at a specific moment in time, not for a
specific hemoglobin value, and RBC transfusion
must be avoided whenever possible.
ACUTE ANEMIA, HEMODILUTION AND
ANEMIA TOLERANCE (THE INDIVIDUAL
PHYSIOLOGICAL APPROACH)
Only 0.3ml of oxygen is dissolved physically
in 100ml of blood at room air breathing (FiO2
0.21 and atmospheric pressure 1013mbar), but it
can play a vital role in severe acute anemia states.
With a FiO2 of 1.0 and a hemoglobin value of
10 g/l, the physically dissolved amount of oxygen
equals the amount of oxygen bound to hemoglobin
[62]. Survival of transient acute anemia (hemo-
globin 7 g/l) was reported [63]. Even without
allogeneic blood transfusion, a nadir hemoglobin
of 14 g/l was survived by a patient refusing blood
products [64].
Cellular and circulatory physiological compen-
satory mechanisms facilitate vital oxygen delivery
to the tissues (DO2) during anemia [65
&
]. DO2 is the
product of cardiac output and arterial oxygen con-
tent of the blood. The body’s demand for oxygen is
five-fold exceeded by DO2 in physiological con-
ditions. Moreover, a rise in cardiac output and an
increase in O2 extraction can compensate for a
decline in the oxygen content of the blood in states
of acute anemia [66].
A critical hemoglobin value [Hb(crit)] is reached
when whole body oxygen consumption (VO2) starts
to decline because of insufficient DO2 (¼global
body hypoxia). In an animal model, all of the study
pigs consecutively died within 3h after reaching the
Trauma
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Hb(crit) with a FiO2 of 0.21 [67]. Increasing the FiO2
leads to more physically dissolved oxygen, resulting
in a lower Hb(crit) and a higher level of possible
hemodilution [68
&
].
In addition, Lauscher et al. [69
&&
] demonstrated
that there are organ-specific thresholds of anemic
hypoxia in anesthetized pigs. Kidney and skeletal
muscle showed tissue hypoxia before reaching
Hb(crit) and significantly earlier than cardiac
ventricleandbrain.Onthecontrary, the liver showed
even fewer cellular signs of hypoxia at a hemoglobin
level of 40g/l compared with the control group (nor-
mal hemoglobin values) [69
&&
]. The impact of this
animal model data is unclear for the time being.
Further investigations need to be performed to elu-
cidate the clinical relevance in the human body.
Moreover, current transfusion thresholds (70g/l)
are high above the critical individual organ margin
described in the animal study.
Other clinically susceptible factors to increase
anemia tolerance are deep neuromuscular blockade
[70], hypothermia, by reducing (cerebral) oxygen
consumption by 6% per degree Celsius [71] and
administration of norepinephrine to overcome arte-
rial hypotension during hemodilution [72].
This growing knowledge may lead to a better
understanding of the role of transfusion in the
context of severe traumatic bleeding. Measures to
increase anemia tolerance, further insights into
organ-specific oxygen demand and assessment of
organ ischemia thresholds may reveal new physio-
logic triggers to guide red cell transfusion therapy in
the future.
ALTERNATIVES TO ALLOGENEIC BLOOD
PRODUCTS
Actual studies clearly show that a high amount
of RBCs, fresh frozen plasmas (FFPs) and platelets
can be reduced without additional risks for
patients by using transfusion algorithms in trauma
on the basis of coagulation factor concentrates
[73,74]. Data from four European countries (United
Kingdom, Germany, Italy and Switzerland) were
used to calculate blood substitution and costs of
blood products needed. The results showed that
these products account for approximately one
third of all costs associated with trauma care [75].
The reduction of septic complications and
organ failure tends to reduce days on ventilator,
whilst on ICU and shorten overall in-hospital
LOS which clearly contribute to cost reduction in
trauma care without increasing the risk of patients
[76].
The use of POC devices as well as goal-
directed algorithms is getting essential (Fig. 1)
[77
&&
]. Because of their use, coagulopathy in trauma
can be treated early and effectively and blood loss
and the use of blood products can be reduced
[1
&&
,78
&&
,79
&&
].
Thromboelastometry (ROTEM) measures and
graphically displays the viscoelasticity of the devel-
oping blood clot. The first usable results are pro-
vided within 5–10min, whereas the classical
laboratory results may take from 30 to 90min and
thereby delay effective therapy for patients [77
&&
].
Details on the ROTEM method and technology are
to be found in the literature [80]. Another device to
be used is the thromboelastography (TEG, Haemo-
scope Corporation, Niles, Illinois, USA) working
similarly to the ROTEM, details are described in
the literature [81]. The use of POC devices is acutely
clearly recommended by the European Trauma
Guidelines [1
&&
].
The use of FFP leads to adverse effects that are
similar to those of RBCs (increased mortality,
multiple organ failure, infections, lung injury,
immunomodulation) [82
&
]. The use of FFP is getting
more and more questionable as concentrations of
factors are variable and large volumes are necessary
to achieve an effect. Actually, the use of fibrinogen
concentrates is favorable compared with FFPs [83].
According to the European Trauma Guidelines, the
use of FFP or fibrinogen is indicated in patients with
massive transfusions. A ratio of 1 : 2 (FFP : RBC) is
suggested if FFP is being used. However, in non-
massive bleeding, plasma transfusion should be
avoided [1
&&
]. Fibrinogen has been shown to be
the coagulation factor which drops critically first
during bleeding; for this reason, its concentration
needs to bemonitored closely [1
&&
,73,84]. The actual
recommended fibrinogen target levels of 1.5–2.0 g/l
have been defined by the European Trauma Treat-
ment Guidelines [1
&&
]. As the concentration of
fibrinogen in FFP does not exceed 2g/l, the use of
fibrinogen concentrates has the advantage of reach-
ing fibrinogen levels above 2.0 g/l without volume
overload [85]. The second coagulation factor to be
monitored closely is factor XIII which, in combi-
nation with fibrinogen, is essential for a stable clot;
its level should bemaintained above 60% by admin-
istration of factor concentrate in case of active
bleeding [86–89]. In addition to those single-factor
concentrates, prothrombin complex concentrates
may be taken into consideration [73,89–93]. There
are different types of prothrombin complex concen-
trates regarding factors contained (three vs. four),
their relative composition and their thrombotic
potential. Their use in trauma is recommended
since 2013, but only under strict surveillance by
rotational thromboelastometry and in the context
of algorithms, which suggest small and repeated
Transfusion strategy in multiple trauma patients Theusinger et al.
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Diagnogstic Intervention
Preoperative history
1. Drugs affecting coagulation
- Antiplatelet drugs 
- Heparin
- Oral anticoagulation (Vit. K antagonists,
Xa antagonists, IIa  antagonists)
2. Coagulation status?
3. HIT II? 
ROTEM after anesthesia induction
- Transplant surgery
- Cardiac and vascular surgery
- Difficult cancer surgery 
- Liver insufficiency
- Intra-abdominal sepsis
- Emergency room entry
Blood loss > 50% with diffuse bleeding
ROTEM analysis
- EXTEM, INTEM, FIBTEM, APTEM
- HEPTEM in heart and vascular surgery
Target values
- Normothermia (temp. > 35°C)
- Normocalcemia (Ca >1.15 mmol/l)
- No acidosis (pH > 7.2)
- Hematocrit > 0.21
- Hypotension (MAP 55–60 mmHg)
Crystalloid and/or colloid volume substitution
FIBTEM < 7 mm Fibrinogen 2–4 g i.v. ( maximal 3x2g), after a total of 6 g give  FXIII
INTEM (CT and CFT prolonged) and HEPTEM normal
OR
ACT pathological and heparinase ACT normal
Protamine sulfate 1:1 to heparin 
crystalloid and colloid volume substitution
EXTEM / INTEM: 
Decrease of MCF after maximum was reached
APTEM: normal
Hyperfibrinolysis
Tranexamic acid 
- 15 mg/kg BW as bolus i.v.
- 1–2 mg/kg/h during surgery i.v. as perfusion
On-going diffuse bleeding 
EXTEM /INTEM MCF<40 mm
CT EXTEM /INTEM normal
MCF FIBTEM <7 mm
Hct > 0.21
MCF FIBTEM > 7mm
Platelets < 50 000/ µl  (< 100 000/ µl in cardiac surgery or in 
patients suffering from traumatic brain injury)
Coagulation test incl. F XIII, F V, INR, PT, aPTT
Fibrinogen up to 6 g, followed by Factor XIII 15 U/kg BW 
crystalloid and colloid volume substitution
Platelet concentrates
Target of Factor XIII:  > 60% (Factor XIII 15 U/kg BW)
Target of Factor V: >20% (in particular in liver insufficiency
/trauma or intra-abdominal sepsis: 2–4 U FFP)
On-going diffuse bleeding
Quick's value < 30% and
Factor V > 20 %
OR
EXTEM/INTEM: CT, CFT prolonged
4 factor prothrombin complex concentrate 1000–2000 IU
- Factor II, VII, IX and X
Depending on the patient’s bodyweight
In case of massive transfusion Target hematocrit: 0.21 –0.24
If massive diffuse bleeding continues and
Treated acidosis
Treated hypothermia
Excluded hypocalcemia
Hematocrit: 0.21–0.24
Excluded DIC
Fibrinogen was substituted
Platelets >50 000/µl (>100 000/µl in cardiac surgery or in 
patients suffering from traumatic brain injury)
Recombinant Factor VIIa 
60 µg/kg bodyweight i.v.
A second dose of 60 µg/kg bodyweight i.v. can be given again
after 2–4 hours, if bleeding has not completely stopped. 
FIGURE 1. Third version of the transfusion algorithm of the University Hospital of Zu¨rich 2013, Switzerland. BW, body weight;
CFT, clot formation time; FFP, fresh frozen plasma; HIT, heparin-induced thrombocytopenia; INR, international normalized ratio;
i.v., intravenous; MAP, mean arterial pressure; MCF, maximal clot firmness. Adapted with permission [77&&].
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doses to prevent thromboembolic adverse events
[1
&&
,92].
In addition to all factor concentrates, one should
take the two following drugs into consideration: first,
tranexamic acid (TXA), which stops hyperfibrinoly-
sis, reduces theneed for bloodproducts anddecreases
mortality [94] and second, desmopressin, which
enhances platelet adherence [94–99]. There is
actually clear evidence that the early use of TXA is
favorable for patients. One study, including 40
trauma patients (55% penetrating, 45% blunt
trauma), all received TXA in the prehospital setting
showing that this is feasible without delaying
treatment or creating severe adverse events [100
&&
].
However, patients’ outcome could not be assessed
because of the study design and the limited sample
size. The most known study, named CRASH-2,
showed that early (within first 3h) administration
of TXA in the emergency room reduces mortality
significantly [94]. Furthermore, TXA is cost effective
and has been integrated into military trauma algo-
rithms [101
&&
]. A recent systematic Cochrane review
showed that TXA clearly reduces blood transfusions
in patients requiring emergency or urgent surgery
[102
&
].
Regarding desmopressin, the European Trauma
Guidelines recommend a single dose for trauma
patients treated with aspirin [1
&&
].
TRANSFUSION AND PATIENT OUTCOME
Today, in many countries, the widespread approach
is to transfuse bleeding trauma patients with FFP
and RBCs at a 1 : 1 ratio. Halmin et al. [103] recently
published a cohort study on the association between
death in trauma and FFP :RBC ratio integrating
time-dependent data, as suggested by Ho et al.
[104]. In their retrospective cohort study including
nearly 750 patients from one single trauma center,
they analyzed time-dependent transfusions and the
relative risk of death comparing low and high
FFP :RBC ratios. They could find no significant
association between the low plasma ratio and the
risk of death. On the other side, when analyses were
made excluding the time factor, a strong effect of
high plasma ratios was seen, clearly pointing out a
survival bias [103]. This high FFP : RBC regimen is
supported by observational studies mainly from
recent wars, showing lower mortality in bleeding
patients receiving equal volumes of plasma and
RBCs as compared with patients treated with a lower
FFP : RBC ratio. The rationale for this practice is still
unclear with several studies failing to show any
survival benefits of increased plasma use, perhaps
because of a failure to account for the timing of
transfused units. The FFP : RBC ratio measured 24h
after admission was based primarily on war casual-
ties, inwhich it was realized that RBCs alone have no
effect on coagulation but the addition of FFP ameli-
orates coagulation.
The observation of a higher survival rate in
patients having received an equivalent number of
FFP and RBC transfusion at 24h after admission,
however, suffers from this ‘survival bias’. Several
studies have addressed this issue. Ho et al.
[104,105] were able to show that there is a time-
dependent covariate regarding high FFP : RBC ratios
and so far, the current available evidence is incon-
clusive. Any retrospective analysis favors patients
having received high FFP : RBC ratio because only
they survived long enough to receive high amounts
of FFP. Those dying early did not survive long
enough to have FFPs being ready to be administered
[106,107
&&
]. This dilemma can only be solved with
prospective randomized studies. Nascimento et al.
[107
&&
] indeed published in 2013 such a prospective
randomized controlled study with 78 patients
assessing the feasibility of such a study and the effect
on mortality and complications in severe trauma
patients. Patients were randomly assigned to a fixed
ratio of 1 : 1 : 1 transfusion (1 unit of RBC, FFP and
platelets) (n¼40) or to a laboratory guided trans-
fusion protocol which served as the control group
(n¼38) [107&&]. The all-cause 28-day mortality was
32% in the fixed-ratio group compared to 14% in the
control group and thus increased by a relative risk of
2.27 (95% CI 0.98–9.63). Event-free survival was
54% in the patients with fixed ratios compared to
78% in the control group (P¼0.053). The fixed-ratio
transfusion protocol was feasible but associatedwith
large plasma wastage and a near significantly higher
mortality [107
&&
].
There is a great need for further studies on this
subject to clearly identify the optimal treatment of
massively bleeding trauma patients. Furthermore, it
has recently been shown that there is a clear causa-
tion between blood transfusions and bad outcome,
this may also be true in trauma patients and thus
one should consider giving as little blood as possible
and as much as necessary in order to have a better
outcome [108]. This can be guided by a clear algor-
ithm that has to be followed by the whole staff in
charge. Theusinger et al. [77
&&
] recently published a
good example for a feasible algorithm.
CONCLUSION
Transfusion in trauma has to be an individual
decision for a specific patient, not for a specific
laboratory value. Transfusion management must
aim on reducing or even avoiding the use of allo-
geneic blood products. This may lead to a new gold
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standard with cost reduction and amelioration of
outcome of major trauma patients.
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